NO329898B1 - Pteridin forbindelser, fremgangsmate for fremstilling av slike, mellomprodukter, farmasoytiske sammensetninger og fremstilling omfattende slike, anvendelsen av slike i terapi samt anvendelse for fremstilling av medikamenter for behandling av sykdom - Google Patents
Pteridin forbindelser, fremgangsmate for fremstilling av slike, mellomprodukter, farmasoytiske sammensetninger og fremstilling omfattende slike, anvendelsen av slike i terapi samt anvendelse for fremstilling av medikamenter for behandling av sykdom Download PDFInfo
- Publication number
- NO329898B1 NO329898B1 NO20024005A NO20024005A NO329898B1 NO 329898 B1 NO329898 B1 NO 329898B1 NO 20024005 A NO20024005 A NO 20024005A NO 20024005 A NO20024005 A NO 20024005A NO 329898 B1 NO329898 B1 NO 329898B1
- Authority
- NO
- Norway
- Prior art keywords
- thio
- amino
- pteridinone
- methyl
- hydroxy
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 54
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 24
- 238000011282 treatment Methods 0.000 title claims description 20
- 201000010099 disease Diseases 0.000 title claims description 19
- 238000004519 manufacturing process Methods 0.000 title claims description 10
- 239000003814 drug Substances 0.000 title claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 9
- 238000002560 therapeutic procedure Methods 0.000 title claims description 6
- 238000002360 preparation method Methods 0.000 title description 11
- 239000000543 intermediate Substances 0.000 title description 4
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 125000001042 pteridinyl group Chemical class N1=C(N=CC2=NC=CN=C12)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 158
- -1 4-[[(1R)-2-hydroxy-1-methylethyl]amino]-2-[(phenylmethyl)thio]-6H-pyrimido[5,4- b][1,4]thiazin-7(8H)-one 2-[[(2,3-difluorophenyl)methyl]thio]-4-[[(1R)-2-hydroxy-1-methylethyl]amino]- 7(8H)-pteridinone Chemical compound 0.000 claims description 81
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 80
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 65
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 37
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 35
- 125000001424 substituent group Chemical group 0.000 claims description 27
- 125000005843 halogen group Chemical group 0.000 claims description 26
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- 239000001257 hydrogen Substances 0.000 claims description 19
- 239000012453 solvate Substances 0.000 claims description 17
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 12
- 102000019034 Chemokines Human genes 0.000 claims description 11
- 108010012236 Chemokines Proteins 0.000 claims description 11
- 102000002791 Interleukin-8B Receptors Human genes 0.000 claims description 11
- 108010018951 Interleukin-8B Receptors Proteins 0.000 claims description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 201000004681 Psoriasis Diseases 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 6
- 102000009410 Chemokine receptor Human genes 0.000 claims description 6
- 108050000299 Chemokine receptor Proteins 0.000 claims description 6
- 230000033115 angiogenesis Effects 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000006239 protecting group Chemical group 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 5
- 125000001624 naphthyl group Chemical group 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- GBYQXRXPWVJJBZ-MRVPVSSYSA-N 2-[(2,4-difluorophenyl)methylsulfanyl]-4-[[(2r)-1-hydroxypropan-2-yl]amino]-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(N[C@@H](CO)C)=NC=1SCC1=CC=C(F)C=C1F GBYQXRXPWVJJBZ-MRVPVSSYSA-N 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 3
- WAELWVTWUVIVOT-UHFFFAOYSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]-4-(4-hydroxybutylamino)-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(NCCCCO)=NC=1SCC1=CC=CC(F)=C1F WAELWVTWUVIVOT-UHFFFAOYSA-N 0.000 claims description 3
- IEYXQZGBLLSFKG-UHFFFAOYSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]-4-(propan-2-ylamino)-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(NC(C)C)=NC=1SCC1=CC=CC(F)=C1F IEYXQZGBLLSFKG-UHFFFAOYSA-N 0.000 claims description 3
- UTOOXLQVJXOFGP-UHFFFAOYSA-N 2-[[2-[(2,3-difluorophenyl)methylsulfanyl]-7-oxo-8h-pteridin-4-yl]amino]acetamide Chemical compound N=1C=2NC(=O)C=NC=2C(NCC(=O)N)=NC=1SCC1=CC=CC(F)=C1F UTOOXLQVJXOFGP-UHFFFAOYSA-N 0.000 claims description 3
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 3
- HZGHBWDDKDWILV-UHFFFAOYSA-N 4-(1,3-dihydroxypropan-2-ylamino)-2-[[2-fluoro-3-(trifluoromethyl)phenyl]methylsulfanyl]-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(NC(CO)CO)=NC=1SCC1=CC=CC(C(F)(F)F)=C1F HZGHBWDDKDWILV-UHFFFAOYSA-N 0.000 claims description 3
- INAJFJAOCLCRBN-UHFFFAOYSA-N 4-(2-aminoethylamino)-2-[(3-chloro-4-methoxyphenyl)methylsulfanyl]-8h-pteridin-7-one Chemical compound C1=C(Cl)C(OC)=CC=C1CSC1=NC(NCCN)=C(N=CC(=O)N2)C2=N1 INAJFJAOCLCRBN-UHFFFAOYSA-N 0.000 claims description 3
- CMTKAPLMBRIKST-DDWIOCJRSA-N 4-[[(2R)-1-aminopropan-2-yl]amino]-2-[(3-chloro-2-fluorophenyl)methylsulfanyl]-8H-pteridin-7-one hydrochloride Chemical compound Cl.C[C@H](CN)Nc1nc(SCc2cccc(Cl)c2F)nc2[nH]c(=O)cnc12 CMTKAPLMBRIKST-DDWIOCJRSA-N 0.000 claims description 3
- TUQXYDUVFAZOFF-MRVPVSSYSA-N 4-[[(2R)-1-hydroxypropan-2-yl]amino]-2-(thiophen-2-ylmethylsulfanyl)-8H-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(N[C@@H](CO)C)=NC=1SCC1=CC=CS1 TUQXYDUVFAZOFF-MRVPVSSYSA-N 0.000 claims description 3
- WAIHPDZKCSTWKA-SSDOTTSWSA-N 4-[[(2r)-1-hydroxypropan-2-yl]amino]-2-(1,2-oxazol-5-ylmethylsulfanyl)-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(N[C@@H](CO)C)=NC=1SCC1=CC=NO1 WAIHPDZKCSTWKA-SSDOTTSWSA-N 0.000 claims description 3
- OOIPDYWPGUHUJW-UHFFFAOYSA-N 8h-pteridin-7-one Chemical compound C1=NC=NC2=NC(O)=CN=C21 OOIPDYWPGUHUJW-UHFFFAOYSA-N 0.000 claims description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 125000004494 ethyl ester group Chemical group 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical group 0.000 claims description 3
- ZFMOSYKHZBINEE-DDWIOCJRSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]-4-[[(2r)-1-hydroxypropan-2-yl]amino]-8h-pteridin-7-one;sodium Chemical compound [Na].N=1C=2NC(=O)C=NC=2C(N[C@@H](CO)C)=NC=1SCC1=CC=CC(F)=C1F ZFMOSYKHZBINEE-DDWIOCJRSA-N 0.000 claims description 2
- VTVGIRCXYMVRIC-UHFFFAOYSA-N 4-[2-(diethylamino)ethylamino]-2-[(2,3-difluorophenyl)methylsulfanyl]-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(NCCN(CC)CC)=NC=1SCC1=CC=CC(F)=C1F VTVGIRCXYMVRIC-UHFFFAOYSA-N 0.000 claims description 2
- 108091008928 CXC chemokine receptors Proteins 0.000 claims description 2
- 102000054900 CXCR Receptors Human genes 0.000 claims description 2
- BGVPJJAJCFKIFJ-UHFFFAOYSA-N ClC=1C(=C(C=CC1)CSC1=NC=2NC(C=NC2C(=N1)NC(CO)CO)=O)F.ClC=1C(=C(C=CC1)CSC1=NC=2NC(C=NC2C(=N1)NCCO)=O)F Chemical compound ClC=1C(=C(C=CC1)CSC1=NC=2NC(C=NC2C(=N1)NC(CO)CO)=O)F.ClC=1C(=C(C=CC1)CSC1=NC=2NC(C=NC2C(=N1)NCCO)=O)F BGVPJJAJCFKIFJ-UHFFFAOYSA-N 0.000 claims description 2
- QGUWSDDFPSRCDC-UHFFFAOYSA-N FC1=C(CSC2=NC=3NC(C=NC3C(=N2)N(CCC#N)C)=O)C=CC=C1F.FC1=C(CSC2=NC=3NC(C=NC3C(=N2)N(C)CCO)=O)C=CC=C1F Chemical compound FC1=C(CSC2=NC=3NC(C=NC3C(=N2)N(CCC#N)C)=O)C=CC=C1F.FC1=C(CSC2=NC=3NC(C=NC3C(=N2)N(C)CCO)=O)C=CC=C1F QGUWSDDFPSRCDC-UHFFFAOYSA-N 0.000 claims description 2
- DTIRXJJPEUNWJH-DDWIOCJRSA-N FC1=C(CSC2=NC=3NC(C=NC3C(=N2)NCCCO)=O)C=CC=C1F.FC1=C(CSC2=NC=3NC(C=NC3C(=N2)NC[C@@H](C)O)=O)C=CC=C1F Chemical compound FC1=C(CSC2=NC=3NC(C=NC3C(=N2)NCCCO)=O)C=CC=C1F.FC1=C(CSC2=NC=3NC(C=NC3C(=N2)NC[C@@H](C)O)=O)C=CC=C1F DTIRXJJPEUNWJH-DDWIOCJRSA-N 0.000 claims description 2
- BMCBJVGKUUPKOD-UHFFFAOYSA-N FC1=C(CSC2=NC=3NC(C=NC3C(=N2)NCCOCCO)=O)C=CC=C1F.OCCN(C1=NC(=NC=2NC(C=NC12)=O)SCC1=C(C(=CC=C1)F)F)CCO Chemical compound FC1=C(CSC2=NC=3NC(C=NC3C(=N2)NCCOCCO)=O)C=CC=C1F.OCCN(C1=NC(=NC=2NC(C=NC12)=O)SCC1=C(C(=CC=C1)F)F)CCO BMCBJVGKUUPKOD-UHFFFAOYSA-N 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 125000002837 carbocyclic group Chemical group 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 150000003573 thiols Chemical class 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 1
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 claims 1
- ZBGNMCSHQGSFEN-UHFFFAOYSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]-4-(1,3-dihydroxypropan-2-ylamino)-8h-pteridin-7-one;2-[(2,3-difluorophenyl)methylsulfanyl]-4-(2-hydroxyethylamino)-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(NCCO)=NC=1SCC1=CC=CC(F)=C1F.N=1C=2NC(=O)C=NC=2C(NC(CO)CO)=NC=1SCC1=CC=CC(F)=C1F ZBGNMCSHQGSFEN-UHFFFAOYSA-N 0.000 claims 1
- JHMIALYTYYLQDE-UHFFFAOYSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]-4-[ethyl(2-hydroxyethyl)amino]-8h-pteridin-7-one;2-[(2,3-difluorophenyl)methylsulfanyl]-4-[(1-hydroxy-2-methylpropan-2-yl)amino]-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(N(CCO)CC)=NC=1SCC1=CC=CC(F)=C1F.N=1C=2NC(=O)C=NC=2C(NC(C)(CO)C)=NC=1SCC1=CC=CC(F)=C1F JHMIALYTYYLQDE-UHFFFAOYSA-N 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- ZWIFHIVJBVYSOJ-SBSPUUFOSA-N FC1=C(C=CC(=C1)OC)CSC1=NC=2NC(C=NC2C(=N1)N[C@@H](CO)C)=O.FC(C(=O)O)(F)F Chemical compound FC1=C(C=CC(=C1)OC)CSC1=NC=2NC(C=NC2C(=N1)N[C@@H](CO)C)=O.FC(C(=O)O)(F)F ZWIFHIVJBVYSOJ-SBSPUUFOSA-N 0.000 claims 1
- DIPUNMJILBEXGC-MNMPKAIFSA-N FC1=C(CSC2=NC=3NC(C=NC3C(=N2)NCCCCCO)=O)C=CC=C1F.FC1=C(CSC2=NC=3NC(C=NC3C(=N2)N[C@H]2[C@@H](CCC2)O)=O)C=CC=C1F Chemical compound FC1=C(CSC2=NC=3NC(C=NC3C(=N2)NCCCCCO)=O)C=CC=C1F.FC1=C(CSC2=NC=3NC(C=NC3C(=N2)N[C@H]2[C@@H](CCC2)O)=O)C=CC=C1F DIPUNMJILBEXGC-MNMPKAIFSA-N 0.000 claims 1
- CIZZUEUKGNBQPP-UHFFFAOYSA-N ethyl 2-anilino-7-oxo-8-phenylpteridine-6-carboxylate Chemical compound N1=C2N(C=3C=CC=CC=3)C(=O)C(C(=O)OCC)=NC2=CN=C1NC1=CC=CC=C1 CIZZUEUKGNBQPP-UHFFFAOYSA-N 0.000 claims 1
- 239000013067 intermediate product Substances 0.000 claims 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 173
- 238000004949 mass spectrometry Methods 0.000 description 104
- 239000000047 product Substances 0.000 description 73
- 238000005481 NMR spectroscopy Methods 0.000 description 50
- 239000007787 solid Substances 0.000 description 36
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 239000000243 solution Substances 0.000 description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- 239000000203 mixture Substances 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 239000002904 solvent Substances 0.000 description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 21
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- DIKBFYAXUHHXCS-UHFFFAOYSA-N bromoform Chemical compound BrC(Br)Br DIKBFYAXUHHXCS-UHFFFAOYSA-N 0.000 description 12
- 238000001914 filtration Methods 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- 206010039083 rhinitis Diseases 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
- IFLVGRRVGPXYON-UHFFFAOYSA-N adci Chemical compound C12=CC=CC=C2C2(C(=O)N)C3=CC=CC=C3CC1N2 IFLVGRRVGPXYON-UHFFFAOYSA-N 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 229910052708 sodium Inorganic materials 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 6
- 229910052794 bromium Inorganic materials 0.000 description 6
- 229950005228 bromoform Drugs 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- TYEYBOSBBBHJIV-UHFFFAOYSA-M 2-oxobutanoate Chemical compound CCC(=O)C([O-])=O TYEYBOSBBBHJIV-UHFFFAOYSA-M 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 235000019270 ammonium chloride Nutrition 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- BKMMTJMQCTUHRP-GSVOUGTGSA-N (2r)-2-aminopropan-1-ol Chemical compound C[C@@H](N)CO BKMMTJMQCTUHRP-GSVOUGTGSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 102000004890 Interleukin-8 Human genes 0.000 description 4
- 108090001007 Interleukin-8 Proteins 0.000 description 4
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229940031098 ethanolamine Drugs 0.000 description 4
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 4
- 229940096397 interleukin-8 Drugs 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- QHAIWKDCYWFSRO-SECBINFHSA-N 2-(1,3-benzodioxol-4-ylmethylsulfanyl)-4-[[(2r)-1-hydroxypropan-2-yl]amino]-8h-pteridin-7-one Chemical compound N1C(=O)C=NC2=C1N=C(SCC=1C=3OCOC=3C=CC=1)N=C2N[C@@H](CO)C QHAIWKDCYWFSRO-SECBINFHSA-N 0.000 description 3
- VVPXNDSTCCXUJS-UHFFFAOYSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]-4-(1,3-dihydroxypropan-2-ylamino)-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(NC(CO)CO)=NC=1SCC1=CC=CC(F)=C1F VVPXNDSTCCXUJS-UHFFFAOYSA-N 0.000 description 3
- WFCRHCALRXGMDB-SSDOTTSWSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]-4-[[(2r)-1-hydroxypropan-2-yl]amino]-6-(trifluoromethyl)-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C(C(F)(F)F)=NC=2C(N[C@@H](CO)C)=NC=1SCC1=CC=CC(F)=C1F WFCRHCALRXGMDB-SSDOTTSWSA-N 0.000 description 3
- JIKISISMEWPQJK-SECBINFHSA-N 2-[(3-fluoro-2-methoxyphenyl)methylsulfanyl]-4-[[(2r)-1-hydroxypropan-2-yl]amino]-8h-pteridin-7-one Chemical compound COC1=C(F)C=CC=C1CSC1=NC(N[C@H](C)CO)=C(N=CC(=O)N2)C2=N1 JIKISISMEWPQJK-SECBINFHSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- JADSAZFRNNCPEG-MRVPVSSYSA-N 2-[[2-fluoro-3-(trifluoromethyl)phenyl]methylsulfanyl]-4-[[(2r)-1-hydroxypropan-2-yl]amino]-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(N[C@@H](CO)C)=NC=1SCC1=CC=CC(C(F)(F)F)=C1F JADSAZFRNNCPEG-MRVPVSSYSA-N 0.000 description 3
- KJJPLEZQSCZCKE-UHFFFAOYSA-N 2-aminopropane-1,3-diol Chemical compound OCC(N)CO KJJPLEZQSCZCKE-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108010001478 Bacitracin Proteins 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 229960003071 bacitracin Drugs 0.000 description 3
- 229930184125 bacitracin Natural products 0.000 description 3
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 239000002975 chemoattractant Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- UMJTYEUXQGJEIZ-UHFFFAOYSA-N (2-fluorophenyl)methanethiol Chemical compound FC1=CC=CC=C1CS UMJTYEUXQGJEIZ-UHFFFAOYSA-N 0.000 description 2
- XMGPQXNGSBRNSK-UHFFFAOYSA-N 1,2-oxazol-5-ylmethanethiol Chemical compound SCC1=CC=NO1 XMGPQXNGSBRNSK-UHFFFAOYSA-N 0.000 description 2
- FTBSGSZZESQDBM-UHFFFAOYSA-N 1-(bromomethyl)-2,3-difluorobenzene Chemical compound FC1=CC=CC(CBr)=C1F FTBSGSZZESQDBM-UHFFFAOYSA-N 0.000 description 2
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 2
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 2
- ALHFTXQQJSWTIT-UHFFFAOYSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]-4-(2-hydroxyethylamino)-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(NCCO)=NC=1SCC1=CC=CC(F)=C1F ALHFTXQQJSWTIT-UHFFFAOYSA-N 0.000 description 2
- OYXOKEJCXORTSX-UHFFFAOYSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]-4-(5-hydroxypentylamino)-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(NCCCCCO)=NC=1SCC1=CC=CC(F)=C1F OYXOKEJCXORTSX-UHFFFAOYSA-N 0.000 description 2
- RXPRXSUPVUTRNH-UHFFFAOYSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]-4-[(1,3-dihydroxy-2-methylpropan-2-yl)amino]-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(NC(CO)(CO)C)=NC=1SCC1=CC=CC(F)=C1F RXPRXSUPVUTRNH-UHFFFAOYSA-N 0.000 description 2
- WMULXQQZGJWZPZ-VXGBXAGGSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]-4-[[(1r,2r)-2-hydroxycyclopentyl]amino]-8h-pteridin-7-one Chemical compound O[C@@H]1CCC[C@H]1NC1=NC(SCC=2C(=C(F)C=CC=2)F)=NC2=C1N=CC(=O)N2 WMULXQQZGJWZPZ-VXGBXAGGSA-N 0.000 description 2
- OVXYSFQPCQGNRH-GFCCVEGCSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]-4-[[(2r)-1-hydroxy-4-methylpentan-2-yl]amino]-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(N[C@@H](CO)CC(C)C)=NC=1SCC1=CC=CC(F)=C1F OVXYSFQPCQGNRH-GFCCVEGCSA-N 0.000 description 2
- AHVAHTPEQANPQA-MRVPVSSYSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]-4-[[(2r)-1-hydroxypropan-2-yl]amino]-6-methyl-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C(C)=NC=2C(N[C@@H](CO)C)=NC=1SCC1=CC=CC(F)=C1F AHVAHTPEQANPQA-MRVPVSSYSA-N 0.000 description 2
- LTHIETOWBQBYAF-MRVPVSSYSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]-4-[[(2r)-1-hydroxypropan-2-yl]amino]-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(N[C@@H](CO)C)=NC=1SCC1=CC=CC(F)=C1F LTHIETOWBQBYAF-MRVPVSSYSA-N 0.000 description 2
- CTMLHRHDVSWSQE-UHFFFAOYSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]-4-[ethyl(2-hydroxyethyl)amino]-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(N(CCO)CC)=NC=1SCC1=CC=CC(F)=C1F CTMLHRHDVSWSQE-UHFFFAOYSA-N 0.000 description 2
- RIZMZPFNCPWNAH-SNVBAGLBSA-N 2-[(2-fluoro-3-methylphenyl)methylsulfanyl]-4-[[(2r)-1-hydroxypropan-2-yl]amino]-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(N[C@@H](CO)C)=NC=1SCC1=CC=CC(C)=C1F RIZMZPFNCPWNAH-SNVBAGLBSA-N 0.000 description 2
- FFWWPOSWGBRMAI-SECBINFHSA-N 2-[(2-fluorophenyl)methylsulfanyl]-4-[[(2r)-1-hydroxypropan-2-yl]amino]-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(N[C@@H](CO)C)=NC=1SCC1=CC=CC=C1F FFWWPOSWGBRMAI-SECBINFHSA-N 0.000 description 2
- QPYBUNKIFZAIGH-MRVPVSSYSA-N 2-[(3-chloro-2-fluorophenyl)methylsulfanyl]-4-[[(2r)-1-hydroxypropan-2-yl]amino]-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(N[C@@H](CO)C)=NC=1SCC1=CC=CC(Cl)=C1F QPYBUNKIFZAIGH-MRVPVSSYSA-N 0.000 description 2
- HPXRXXAUEJXEJK-UHFFFAOYSA-N 2-[(3-chloro-4-methoxyphenyl)methylsulfanyl]-4-(1,3-dihydroxypropan-2-ylamino)-8h-pteridin-7-one Chemical compound C1=C(Cl)C(OC)=CC=C1CSC1=NC(NC(CO)CO)=C(N=CC(=O)N2)C2=N1 HPXRXXAUEJXEJK-UHFFFAOYSA-N 0.000 description 2
- OCMQNGZAZIYPPZ-SECBINFHSA-N 2-[(3-chlorophenyl)methylsulfanyl]-4-[[(2r)-1-hydroxypropan-2-yl]amino]-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(N[C@@H](CO)C)=NC=1SCC1=CC=CC(Cl)=C1 OCMQNGZAZIYPPZ-SECBINFHSA-N 0.000 description 2
- WVNDNQWPAYCUBF-UHFFFAOYSA-N 2-[[2-fluoro-3-(trifluoromethyl)phenyl]methylsulfanyl]-4-(2-hydroxyethylamino)-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(NCCO)=NC=1SCC1=CC=CC(C(F)(F)F)=C1F WVNDNQWPAYCUBF-UHFFFAOYSA-N 0.000 description 2
- SREFYUVGXDLALM-SECBINFHSA-N 2-[[4-(difluoromethoxy)phenyl]methylsulfanyl]-4-[[(2r)-1-hydroxypropan-2-yl]amino]-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(N[C@@H](CO)C)=NC=1SCC1=CC=C(OC(F)F)C=C1 SREFYUVGXDLALM-SECBINFHSA-N 0.000 description 2
- GGPSNLGKGBWVSH-SNVBAGLBSA-N 2-benzylsulfanyl-4-[[(2r)-1-hydroxypropan-2-yl]amino]-8h-pyrimido[5,4-b][1,4]thiazin-7-one Chemical compound N=1C=2NC(=O)CSC=2C(N[C@@H](CO)C)=NC=1SCC1=CC=CC=C1 GGPSNLGKGBWVSH-SNVBAGLBSA-N 0.000 description 2
- OKTVAUNSMLMTBE-UHFFFAOYSA-N 4-(1,3-dihydroxypropan-2-ylamino)-2-(thiophen-2-ylmethylsulfanyl)-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(NC(CO)CO)=NC=1SCC1=CC=CS1 OKTVAUNSMLMTBE-UHFFFAOYSA-N 0.000 description 2
- VODJJGQOLOEIRR-UHFFFAOYSA-N 4-(2-aminoethylamino)-2-[[2-fluoro-3-(trifluoromethyl)phenyl]methylsulfanyl]-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(NCCN)=NC=1SCC1=CC=CC(C(F)(F)F)=C1F VODJJGQOLOEIRR-UHFFFAOYSA-N 0.000 description 2
- PNLILNSUFARULY-LLVKDONJSA-N 4-[[(2r)-1-hydroxypropan-2-yl]amino]-2-[(3-methylphenyl)methylsulfanyl]-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(N[C@@H](CO)C)=NC=1SCC1=CC=CC(C)=C1 PNLILNSUFARULY-LLVKDONJSA-N 0.000 description 2
- MEUIOCMLELSKDI-MRVPVSSYSA-N 4-[[(2r)-1-hydroxypropan-2-yl]amino]-2-[(5-methylfuran-2-yl)methylsulfanyl]-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(N[C@@H](CO)C)=NC=1SCC1=CC=C(C)O1 MEUIOCMLELSKDI-MRVPVSSYSA-N 0.000 description 2
- QQYSUMFYUUZAML-UHFFFAOYSA-N 4-bromo-2-[(2,3-difluorophenyl)methylsulfanyl]-8h-pteridin-7-one Chemical compound FC1=CC=CC(CSC=2N=C3NC(=O)C=NC3=C(Br)N=2)=C1F QQYSUMFYUUZAML-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 2
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 description 2
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 206010014950 Eosinophilia Diseases 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- OZLGRUXZXMRXGP-UHFFFAOYSA-N Fluo-3 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)N(CC(O)=O)CC(O)=O)=C1 OZLGRUXZXMRXGP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 2
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 description 2
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000721454 Pemphigus Species 0.000 description 2
- 102100036154 Platelet basic protein Human genes 0.000 description 2
- 229910004298 SiO 2 Inorganic materials 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- YZUUXDGXNGQIPG-UHFFFAOYSA-N acetic acid;(2-fluoro-5-methylphenyl)methanethiol Chemical compound CC(O)=O.CC1=CC=C(F)C(CS)=C1 YZUUXDGXNGQIPG-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- XORXDJBDZJBCOC-UHFFFAOYSA-N azanium;acetonitrile;acetate Chemical compound [NH4+].CC#N.CC([O-])=O XORXDJBDZJBCOC-UHFFFAOYSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 108010035886 connective tissue-activating peptide Proteins 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 201000002491 encephalomyelitis Diseases 0.000 description 2
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002140 halogenating effect Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 239000011539 homogenization buffer Substances 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000010829 isocratic elution Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 210000000274 microglia Anatomy 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 2
- 229940116357 potassium thiocyanate Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000012536 storage buffer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 125000004001 thioalkyl group Chemical group 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- GCZQHDFWKVMZOE-UHFFFAOYSA-N thiophen-2-ylmethanethiol Chemical compound SCC1=CC=CS1 GCZQHDFWKVMZOE-UHFFFAOYSA-N 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- OVVKITNMPZZCSS-UHFFFAOYSA-N (2,4-difluorophenyl)methanethiol Chemical compound FC1=CC=C(CS)C(F)=C1 OVVKITNMPZZCSS-UHFFFAOYSA-N 0.000 description 1
- CTSJNFCAVJCGRQ-UHFFFAOYSA-N (2-fluoro-3-methylphenyl)methanethiol Chemical compound CC1=CC=CC(CS)=C1F CTSJNFCAVJCGRQ-UHFFFAOYSA-N 0.000 description 1
- HOJFSTIGISSQIU-UHFFFAOYSA-N (2-fluoro-4-methoxyphenyl)methanethiol Chemical compound COC1=CC=C(CS)C(F)=C1 HOJFSTIGISSQIU-UHFFFAOYSA-N 0.000 description 1
- KJNSKKLMCXORGH-UHFFFAOYSA-N (2-fluoro-5-methylphenyl)methanol Chemical compound CC1=CC=C(F)C(CO)=C1 KJNSKKLMCXORGH-UHFFFAOYSA-N 0.000 description 1
- FIAINKIUSZGVGX-HSHFZTNMSA-N (2r)-2-aminopropanamide;hydrochloride Chemical compound Cl.C[C@@H](N)C(N)=O FIAINKIUSZGVGX-HSHFZTNMSA-N 0.000 description 1
- SOXZOCWUQRINNR-UHFFFAOYSA-N (3-chloro-2-fluorophenyl)methanethiol Chemical compound FC1=C(Cl)C=CC=C1CS SOXZOCWUQRINNR-UHFFFAOYSA-N 0.000 description 1
- ATTHPHKTDGQZSV-UHFFFAOYSA-N (3-chloro-4-methoxyphenyl)methanethiol Chemical compound COC1=CC=C(CS)C=C1Cl ATTHPHKTDGQZSV-UHFFFAOYSA-N 0.000 description 1
- KDLSTBYZKATUIM-UHFFFAOYSA-N (3-chlorophenyl)methanethiol Chemical compound SCC1=CC=CC(Cl)=C1 KDLSTBYZKATUIM-UHFFFAOYSA-N 0.000 description 1
- JHQVNBINSJWDRN-UHFFFAOYSA-N (3-fluoro-2-methoxyphenyl)methanethiol Chemical compound COC1=C(F)C=CC=C1CS JHQVNBINSJWDRN-UHFFFAOYSA-N 0.000 description 1
- QTKGVZYJECZACB-UHFFFAOYSA-N (3-fluoro-2-methoxyphenyl)methanol Chemical compound COC1=C(F)C=CC=C1CO QTKGVZYJECZACB-UHFFFAOYSA-N 0.000 description 1
- PNAZUQUHTIOEHF-UHFFFAOYSA-N (3-methylphenyl)methanethiol Chemical compound CC1=CC=CC(CS)=C1 PNAZUQUHTIOEHF-UHFFFAOYSA-N 0.000 description 1
- MGLMZOFGBDYNMH-UHFFFAOYSA-N (5-methylfuran-2-yl)methanethiol Chemical compound CC1=CC=C(CS)O1 MGLMZOFGBDYNMH-UHFFFAOYSA-N 0.000 description 1
- QUPFKBITVLIQNA-KPKJPENVSA-N (5e)-2-sulfanylidene-5-[[5-[3-(trifluoromethyl)phenyl]furan-2-yl]methylidene]-1,3-thiazolidin-4-one Chemical compound FC(F)(F)C1=CC=CC(C=2OC(\C=C\3C(NC(=S)S/3)=O)=CC=2)=C1 QUPFKBITVLIQNA-KPKJPENVSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- VXYVZJWLPVTLOR-UHFFFAOYSA-N 1,3-benzodioxol-4-ylmethanethiol Chemical compound SCC1=CC=CC2=C1OCO2 VXYVZJWLPVTLOR-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- IBLMYGXJKQIGSN-UHFFFAOYSA-N 1-(bromomethyl)-2,4-difluorobenzene Chemical compound FC1=CC=C(CBr)C(F)=C1 IBLMYGXJKQIGSN-UHFFFAOYSA-N 0.000 description 1
- DCGWFNZSJBIAKE-UHFFFAOYSA-N 1-(bromomethyl)-2-fluoro-3-methylbenzene Chemical compound CC1=CC=CC(CBr)=C1F DCGWFNZSJBIAKE-UHFFFAOYSA-N 0.000 description 1
- HYILLTADABKYHO-UHFFFAOYSA-N 1-(bromomethyl)-3-chloro-2-fluorobenzene Chemical compound FC1=C(Cl)C=CC=C1CBr HYILLTADABKYHO-UHFFFAOYSA-N 0.000 description 1
- IFNMJBFIRKAQBT-UHFFFAOYSA-N 1-(bromomethyl)-4-(difluoromethoxy)benzene Chemical compound FC(F)OC1=CC=C(CBr)C=C1 IFNMJBFIRKAQBT-UHFFFAOYSA-N 0.000 description 1
- KVOKEUYGMDGQSP-UHFFFAOYSA-N 1-(chloromethyl)-2-fluoro-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C(F)=C1 KVOKEUYGMDGQSP-UHFFFAOYSA-N 0.000 description 1
- PLTQMIYVUSUELE-UHFFFAOYSA-N 1-(chloromethyl)-3-fluoro-2-methoxybenzene Chemical compound COC1=C(F)C=CC=C1CCl PLTQMIYVUSUELE-UHFFFAOYSA-N 0.000 description 1
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
- BWSBBVOWYQCJBO-UHFFFAOYSA-N 2-(2-fluoro-5-methylphenyl)ethanethiol Chemical compound CC1=CC=C(F)C(CCS)=C1 BWSBBVOWYQCJBO-UHFFFAOYSA-N 0.000 description 1
- BTOZNNBKJBFVND-UHFFFAOYSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]-4-(3-hydroxypropylamino)-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(NCCCO)=NC=1SCC1=CC=CC(F)=C1F BTOZNNBKJBFVND-UHFFFAOYSA-N 0.000 description 1
- SKTGDFBTGFNMBY-UHFFFAOYSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]-4-(6-hydroxyhexylamino)-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(NCCCCCCO)=NC=1SCC1=CC=CC(F)=C1F SKTGDFBTGFNMBY-UHFFFAOYSA-N 0.000 description 1
- FRJTVWDEDAAIHO-UHFFFAOYSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]-4-(ethylamino)-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(NCC)=NC=1SCC1=CC=CC(F)=C1F FRJTVWDEDAAIHO-UHFFFAOYSA-N 0.000 description 1
- MDSCPOOFSYKXTO-UHFFFAOYSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]-4-[(1-hydroxy-2-methylpropan-2-yl)amino]-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(NC(C)(CO)C)=NC=1SCC1=CC=CC(F)=C1F MDSCPOOFSYKXTO-UHFFFAOYSA-N 0.000 description 1
- TXNASZQQYMYLIE-UHFFFAOYSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]-4-[(3-hydroxy-2,2-dimethylpropyl)amino]-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(NCC(C)(CO)C)=NC=1SCC1=CC=CC(F)=C1F TXNASZQQYMYLIE-UHFFFAOYSA-N 0.000 description 1
- GCNAQTSXCLFRET-UHFFFAOYSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]-4-[2-(2-hydroxyethoxy)ethylamino]-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(NCCOCCO)=NC=1SCC1=CC=CC(F)=C1F GCNAQTSXCLFRET-UHFFFAOYSA-N 0.000 description 1
- DRYFUUVSGBBGLL-UHFFFAOYSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]-4-[2-hydroxyethyl(methyl)amino]-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(N(CCO)C)=NC=1SCC1=CC=CC(F)=C1F DRYFUUVSGBBGLL-UHFFFAOYSA-N 0.000 description 1
- UIURZKDZGVLBOL-SNVBAGLBSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]-4-[[(2r)-1-hydroxybutan-2-yl]amino]-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(N[C@@H](CO)CC)=NC=1SCC1=CC=CC(F)=C1F UIURZKDZGVLBOL-SNVBAGLBSA-N 0.000 description 1
- CTTSXKXRFZXVFC-MRVPVSSYSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]-4-[[(2r)-2-hydroxypropyl]amino]-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(NC[C@H](O)C)=NC=1SCC1=CC=CC(F)=C1F CTTSXKXRFZXVFC-MRVPVSSYSA-N 0.000 description 1
- JMWPBAOXVUZJOH-GFCCVEGCSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]-4-[[(2s)-1-hydroxy-3,3-dimethylbutan-2-yl]amino]-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(N[C@H](CO)C(C)(C)C)=NC=1SCC1=CC=CC(F)=C1F JMWPBAOXVUZJOH-GFCCVEGCSA-N 0.000 description 1
- UIURZKDZGVLBOL-JTQLQIEISA-N 2-[(2,3-difluorophenyl)methylsulfanyl]-4-[[(2s)-1-hydroxybutan-2-yl]amino]-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(N[C@H](CO)CC)=NC=1SCC1=CC=CC(F)=C1F UIURZKDZGVLBOL-JTQLQIEISA-N 0.000 description 1
- LTHIETOWBQBYAF-QMMMGPOBSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]-4-[[(2s)-1-hydroxypropan-2-yl]amino]-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(N[C@H](CO)C)=NC=1SCC1=CC=CC(F)=C1F LTHIETOWBQBYAF-QMMMGPOBSA-N 0.000 description 1
- LUXKMKJKXOMEAN-UHFFFAOYSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]-4-[[3-(dimethylamino)-2,2-dimethylpropyl]amino]-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(NCC(C)(C)CN(C)C)=NC=1SCC1=CC=CC(F)=C1F LUXKMKJKXOMEAN-UHFFFAOYSA-N 0.000 description 1
- UUSHWADNFWAUQP-UHFFFAOYSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]-5-nitrosopyrimidine-4,6-diamine Chemical compound NC1=C(N=O)C(N)=NC(SCC=2C(=C(F)C=CC=2)F)=N1 UUSHWADNFWAUQP-UHFFFAOYSA-N 0.000 description 1
- SYZOJSBWVZKNNP-UHFFFAOYSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]pyrimidine-4,5,6-triamine Chemical compound NC1=C(N)C(N)=NC(SCC=2C(=C(F)C=CC=2)F)=N1 SYZOJSBWVZKNNP-UHFFFAOYSA-N 0.000 description 1
- VMLNQOIISKHWST-UHFFFAOYSA-N 2-[(2,3-difluorophenyl)methylsulfanyl]pyrimidine-4,6-diamine Chemical compound NC1=CC(N)=NC(SCC=2C(=C(F)C=CC=2)F)=N1 VMLNQOIISKHWST-UHFFFAOYSA-N 0.000 description 1
- OVCHPNBASZDTMI-UHFFFAOYSA-N 2-[(2,3-difluorophenyl)methylsulfonyl]-4-(1,3-dihydroxypropan-2-ylamino)-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(NC(CO)CO)=NC=1S(=O)(=O)CC1=CC=CC(F)=C1F OVCHPNBASZDTMI-UHFFFAOYSA-N 0.000 description 1
- YIJCMEMGGDEONS-MRVPVSSYSA-N 2-[(2,3-difluorophenyl)methylsulfonyl]-4-[[(2r)-1-hydroxypropan-2-yl]amino]-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(N[C@@H](CO)C)=NC=1S(=O)(=O)CC1=CC=CC(F)=C1F YIJCMEMGGDEONS-MRVPVSSYSA-N 0.000 description 1
- NLBYCOMIYPGAIY-SECBINFHSA-N 2-[(2-fluoro-4-methoxyphenyl)methylsulfanyl]-4-[[(2r)-1-hydroxypropan-2-yl]amino]-8h-pteridin-7-one Chemical compound FC1=CC(OC)=CC=C1CSC1=NC(N[C@H](C)CO)=C(N=CC(=O)N2)C2=N1 NLBYCOMIYPGAIY-SECBINFHSA-N 0.000 description 1
- KAYXIJOSGHIYGB-SNVBAGLBSA-N 2-[(2-fluoro-5-methylphenyl)methylsulfanyl]-4-[[(2r)-1-hydroxypropan-2-yl]amino]-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(N[C@@H](CO)C)=NC=1SCC1=CC(C)=CC=C1F KAYXIJOSGHIYGB-SNVBAGLBSA-N 0.000 description 1
- MPGKKVURGBVKGW-UHFFFAOYSA-N 2-[(3-chloro-2-fluorophenyl)methylsulfanyl]-4-(2-hydroxyethylamino)-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(NCCO)=NC=1SCC1=CC=CC(Cl)=C1F MPGKKVURGBVKGW-UHFFFAOYSA-N 0.000 description 1
- DJLKHEQCDNCNNC-SECBINFHSA-N 2-[(4-hydroxyphenyl)methylsulfanyl]-4-[[(2r)-1-hydroxypropan-2-yl]amino]-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(N[C@@H](CO)C)=NC=1SCC1=CC=C(O)C=C1 DJLKHEQCDNCNNC-SECBINFHSA-N 0.000 description 1
- UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 description 1
- VFAHBLZHYICEPR-UHFFFAOYSA-N 2-benzylsulfanyl-1,8-dihydropyrimido[5,4-b][1,4]thiazine-4,7-dione Chemical compound N1C(=O)CSC(C(N=2)=O)=C1NC=2SCC1=CC=CC=C1 VFAHBLZHYICEPR-UHFFFAOYSA-N 0.000 description 1
- BAMMZILBCUFCAI-UHFFFAOYSA-N 2-benzylsulfanyl-5-nitrosopyrimidine-4,6-diamine Chemical compound NC1=C(N=O)C(N)=NC(SCC=2C=CC=CC=2)=N1 BAMMZILBCUFCAI-UHFFFAOYSA-N 0.000 description 1
- GVDJEHMDNREMFA-UHFFFAOYSA-N 3,3,3-trifluoro-2-oxopropanoic acid Chemical compound OC(=O)C(=O)C(F)(F)F GVDJEHMDNREMFA-UHFFFAOYSA-N 0.000 description 1
- QCAWOHUJKPKOMD-UHFFFAOYSA-N 4,6-diamino-1h-pyrimidine-2-thione Chemical compound NC1=CC(N)=NC(S)=N1 QCAWOHUJKPKOMD-UHFFFAOYSA-N 0.000 description 1
- NXSORIZRMNGQNL-UHFFFAOYSA-N 4-(bromomethyl)-1,3-benzodioxole Chemical compound BrCC1=CC=CC2=C1OCO2 NXSORIZRMNGQNL-UHFFFAOYSA-N 0.000 description 1
- SMIQKBQAYPOOJL-UHFFFAOYSA-N 4-[bis(2-hydroxyethyl)amino]-2-[(2,3-difluorophenyl)methylsulfanyl]-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(N(CCO)CCO)=NC=1SCC1=CC=CC(F)=C1F SMIQKBQAYPOOJL-UHFFFAOYSA-N 0.000 description 1
- XWCJQMKJKGGDOE-UHFFFAOYSA-N 4-amino-2-[(2,3-difluorophenyl)methylsulfanyl]-6-(trifluoromethyl)-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C(C(F)(F)F)=NC=2C(N)=NC=1SCC1=CC=CC(F)=C1F XWCJQMKJKGGDOE-UHFFFAOYSA-N 0.000 description 1
- UCQWKODTOGLGIZ-UHFFFAOYSA-N 4-amino-2-[(2,3-difluorophenyl)methylsulfanyl]-6-methyl-8h-pteridin-7-one Chemical compound N1=C2NC(=O)C(C)=NC2=C(N)N=C1SCC1=CC=CC(F)=C1F UCQWKODTOGLGIZ-UHFFFAOYSA-N 0.000 description 1
- LUBSJTIQAOZACI-UHFFFAOYSA-N 4-amino-2-[(2,3-difluorophenyl)methylsulfanyl]-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(N)=NC=1SCC1=CC=CC(F)=C1F LUBSJTIQAOZACI-UHFFFAOYSA-N 0.000 description 1
- BOMPWDBCRYSERI-UHFFFAOYSA-N 4-amino-2-[(3-chloro-2-fluorophenyl)methylsulfanyl]-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(N)=NC=1SCC1=CC=CC(Cl)=C1F BOMPWDBCRYSERI-UHFFFAOYSA-N 0.000 description 1
- CNUUYTLFNOMHLA-UHFFFAOYSA-N 4-amino-2-[(3-chloro-4-methoxyphenyl)methylsulfanyl]-8h-pteridin-7-one Chemical compound C1=C(Cl)C(OC)=CC=C1CSC1=NC(N)=C(N=CC(=O)N2)C2=N1 CNUUYTLFNOMHLA-UHFFFAOYSA-N 0.000 description 1
- GRHIFAGWOJPYCZ-UHFFFAOYSA-N 4-amino-2-benzylsulfanyl-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(N)=NC=1SCC1=CC=CC=C1 GRHIFAGWOJPYCZ-UHFFFAOYSA-N 0.000 description 1
- UFMDFMPLTWZIQZ-UHFFFAOYSA-N 4-amino-2-benzylsulfonyl-8h-pteridin-7-one Chemical compound N=1C=2NC(=O)C=NC=2C(N)=NC=1S(=O)(=O)CC1=CC=CC=C1 UFMDFMPLTWZIQZ-UHFFFAOYSA-N 0.000 description 1
- YPGYECFCGWTTNO-UHFFFAOYSA-N 4-bromo-2-[(2,3-difluorophenyl)methylsulfanyl]-6-(trifluoromethyl)-8h-pteridin-7-one Chemical compound FC1=CC=CC(CSC=2N=C3NC(=O)C(=NC3=C(Br)N=2)C(F)(F)F)=C1F YPGYECFCGWTTNO-UHFFFAOYSA-N 0.000 description 1
- DQZLIDOWGARJJD-UHFFFAOYSA-N 4-bromo-2-[(2,3-difluorophenyl)methylsulfanyl]-6-methyl-8h-pteridin-7-one Chemical compound N1=C2NC(=O)C(C)=NC2=C(Br)N=C1SCC1=CC=CC(F)=C1F DQZLIDOWGARJJD-UHFFFAOYSA-N 0.000 description 1
- KCDNXPHDLVBVET-UHFFFAOYSA-N 4-bromo-2-[(3-chloro-2-fluorophenyl)methylsulfanyl]-8h-pteridin-7-one Chemical compound FC1=C(Cl)C=CC=C1CSC1=NC(Br)=C(N=CC(=O)N2)C2=N1 KCDNXPHDLVBVET-UHFFFAOYSA-N 0.000 description 1
- NMHWDDRTDVZKMJ-UHFFFAOYSA-N 4-bromo-2-[(3-chloro-4-methoxyphenyl)methylsulfanyl]-8h-pteridin-7-one Chemical compound C1=C(Cl)C(OC)=CC=C1CSC1=NC(Br)=C(N=CC(=O)N2)C2=N1 NMHWDDRTDVZKMJ-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- IQGYCVKWCYGVBK-UHFFFAOYSA-N 5,6-diamino-1h-pyrimidine-2,4-dithione Chemical compound NC=1NC(=S)NC(=S)C=1N IQGYCVKWCYGVBK-UHFFFAOYSA-N 0.000 description 1
- CBTKGFBIXPMQMD-UHFFFAOYSA-N 6-[[2-fluoro-3-(trifluoromethyl)phenyl]methylsulfanyl]-2-[[3-(trifluoromethyl)phenyl]methylsulfanyl]pyrimidine-4,5-diamine Chemical compound N=1C(SCC=2C(=C(C=CC=2)C(F)(F)F)F)=C(N)C(N)=NC=1SCC1=CC=CC(C(F)(F)F)=C1 CBTKGFBIXPMQMD-UHFFFAOYSA-N 0.000 description 1
- USCKGDQJCBTIGK-UHFFFAOYSA-N 6-amino-2-benzylsulfanyl-1h-pyrimidin-4-one Chemical compound N1C(N)=CC(=O)N=C1SCC1=CC=CC=C1 USCKGDQJCBTIGK-UHFFFAOYSA-N 0.000 description 1
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000035939 Alveolitis allergic Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 201000008283 Atrophic Rhinitis Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- HYBQWTYAKDFFTC-UHFFFAOYSA-N C(C)N(CCNC1=NC(=NC=2NC(C=NC12)=O)SCC1=C(C(=CC=C1)F)F)CC.FC1=C(CSC2=NC=3NC(C=NC3C(=N2)NCC(OC)OC)=O)C=CC=C1F Chemical compound C(C)N(CCNC1=NC(=NC=2NC(C=NC12)=O)SCC1=C(C(=CC=C1)F)F)CC.FC1=C(CSC2=NC=3NC(C=NC3C(=N2)NCC(OC)OC)=O)C=CC=C1F HYBQWTYAKDFFTC-UHFFFAOYSA-N 0.000 description 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 1
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 102100036305 C-C chemokine receptor type 8 Human genes 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 1
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
- 101710155833 C-C motif chemokine 8 Proteins 0.000 description 1
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 description 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 102000001902 CC Chemokines Human genes 0.000 description 1
- 108010040471 CC Chemokines Proteins 0.000 description 1
- 108050006947 CXC Chemokine Proteins 0.000 description 1
- 102000019388 CXC chemokine Human genes 0.000 description 1
- 108010078239 Chemokine CX3CL1 Proteins 0.000 description 1
- 206010057645 Chronic Inflammatory Demyelinating Polyradiculoneuropathy Diseases 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000027445 Farmer Lung Diseases 0.000 description 1
- 206010016228 Fasciitis Diseases 0.000 description 1
- 102000013818 Fractalkine Human genes 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000798902 Homo sapiens Atypical chemokine receptor 4 Proteins 0.000 description 1
- 101000777558 Homo sapiens C-C chemokine receptor type 10 Proteins 0.000 description 1
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 description 1
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 description 1
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 description 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
- 208000009388 Job Syndrome Diseases 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 206010024227 Lepromatous leprosy Diseases 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 1
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910004878 Na2S2O4 Inorganic materials 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 206010060932 Postoperative adhesion Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 206010039088 Rhinitis atrophic Diseases 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 208000020307 Spinal disease Diseases 0.000 description 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 206010044696 Tropical spastic paresis Diseases 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 206010047112 Vasculitides Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- KXDMFMXSCCLTRB-UHFFFAOYSA-N [4-(difluoromethoxy)phenyl]methanethiol Chemical compound FC(F)OC1=CC=C(CS)C=C1 KXDMFMXSCCLTRB-UHFFFAOYSA-N 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000010085 airway hyperresponsiveness Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000025434 cerebellar degeneration Diseases 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000017760 chronic graft versus host disease Diseases 0.000 description 1
- 201000009151 chronic rhinitis Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 125000004212 difluorophenyl group Chemical group 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- YCNWRAXYBQOZRR-NSHDSACASA-N ethyl (2s)-2-[[2-[(2,3-difluorophenyl)methylsulfanyl]-7-oxo-8h-pteridin-4-yl]amino]-3-hydroxypropanoate Chemical compound N=1C=2NC(=O)C=NC=2C(N[C@@H](CO)C(=O)OCC)=NC=1SCC1=CC=CC(F)=C1F YCNWRAXYBQOZRR-NSHDSACASA-N 0.000 description 1
- JIABMYWGFSXHCM-SECBINFHSA-N ethyl 2-[(2,3-difluorophenyl)methylsulfanyl]-4-[[(2r)-1-hydroxypropan-2-yl]amino]-7-oxo-8h-pteridine-6-carboxylate Chemical compound N1=C2NC(=O)C(C(=O)OCC)=NC2=C(N[C@H](C)CO)N=C1SCC1=CC=CC(F)=C1F JIABMYWGFSXHCM-SECBINFHSA-N 0.000 description 1
- AYTWYFREOXSVSB-UHFFFAOYSA-N ethyl 2-[(6-amino-2-benzylsulfanyl-4-oxo-1h-pyrimidin-5-yl)sulfanyl]acetate Chemical compound O=C1C(SCC(=O)OCC)=C(N)NC(SCC=2C=CC=CC=2)=N1 AYTWYFREOXSVSB-UHFFFAOYSA-N 0.000 description 1
- OLMBZHOSDWMNDM-UHFFFAOYSA-N ethyl 4-amino-2-[(2,3-difluorophenyl)methylsulfanyl]-7-oxo-8h-pteridine-6-carboxylate Chemical compound N1=C2NC(=O)C(C(=O)OCC)=NC2=C(N)N=C1SCC1=CC=CC(F)=C1F OLMBZHOSDWMNDM-UHFFFAOYSA-N 0.000 description 1
- MQMYSKDGRVODGS-UHFFFAOYSA-N ethyl 4-bromo-2-[(2,3-difluorophenyl)methylsulfanyl]-7-oxo-8h-pteridine-6-carboxylate Chemical compound N1=C2NC(=O)C(C(=O)OCC)=NC2=C(Br)N=C1SCC1=CC=CC(F)=C1F MQMYSKDGRVODGS-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 208000022195 farmer lung disease Diseases 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 206010051040 hyper-IgE syndrome Diseases 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 238000000670 ligand binding assay Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 208000008585 mastocytosis Diseases 0.000 description 1
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 206010065579 multifocal motor neuropathy Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 208000020469 nerve plexus disease Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 208000012111 paraneoplastic syndrome Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 201000006380 plexopathy Diseases 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
- 208000017443 reproductive system disease Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 208000006961 tropical spastic paraparesis Diseases 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 208000001319 vasomotor rhinitis Diseases 0.000 description 1
- 201000005539 vernal conjunctivitis Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0004128A GB2359551A (en) | 2000-02-23 | 2000-02-23 | Pharmaceutically active pyrimidine derivatives |
PCT/SE2001/000374 WO2001062758A1 (fr) | 2000-02-23 | 2001-02-20 | Composes de pteridine destines au traitement du psoriasis |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20024005D0 NO20024005D0 (no) | 2002-08-22 |
NO20024005L NO20024005L (no) | 2002-10-22 |
NO329898B1 true NO329898B1 (no) | 2011-01-24 |
Family
ID=9886153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20024005A NO329898B1 (no) | 2000-02-23 | 2002-08-22 | Pteridin forbindelser, fremgangsmate for fremstilling av slike, mellomprodukter, farmasoytiske sammensetninger og fremstilling omfattende slike, anvendelsen av slike i terapi samt anvendelse for fremstilling av medikamenter for behandling av sykdom |
Country Status (33)
Country | Link |
---|---|
US (2) | US6875868B2 (fr) |
EP (1) | EP1259512B1 (fr) |
JP (1) | JP2003524012A (fr) |
KR (1) | KR100795758B1 (fr) |
CN (1) | CN1190437C (fr) |
AR (1) | AR029805A1 (fr) |
AT (1) | ATE250605T1 (fr) |
AU (1) | AU782509B2 (fr) |
BG (1) | BG107002A (fr) |
BR (1) | BR0108600A (fr) |
CA (1) | CA2400217C (fr) |
CO (1) | CO5290258A1 (fr) |
CZ (1) | CZ20022839A3 (fr) |
DE (1) | DE60100851T2 (fr) |
DK (1) | DK1259512T3 (fr) |
EE (1) | EE200200461A (fr) |
ES (1) | ES2206402T3 (fr) |
GB (1) | GB2359551A (fr) |
HK (1) | HK1050899A1 (fr) |
HU (1) | HUP0204399A3 (fr) |
IL (2) | IL151132A0 (fr) |
IS (1) | IS6491A (fr) |
MX (1) | MXPA02008233A (fr) |
NO (1) | NO329898B1 (fr) |
NZ (1) | NZ520355A (fr) |
PL (1) | PL358004A1 (fr) |
PT (1) | PT1259512E (fr) |
RU (1) | RU2002125451A (fr) |
SK (1) | SK12152002A3 (fr) |
TR (1) | TR200302214T4 (fr) |
UA (1) | UA72590C2 (fr) |
WO (1) | WO2001062758A1 (fr) |
ZA (1) | ZA200206590B (fr) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9903544D0 (sv) * | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
GB2359078A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
GB2359081A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active thiazolopyrimidines |
GB2359551A (en) * | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
SE0003828D0 (sv) | 2000-10-20 | 2000-10-20 | Astrazeneca Ab | Novel compounds |
CZ20031910A3 (cs) * | 2000-12-11 | 2003-12-17 | Tularik Inc. | Sloučenina s antagonistickými účinky na CXCR3 a farmaceutický postředek |
SE0101322D0 (sv) * | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Novel compounds |
US6794379B2 (en) | 2001-06-06 | 2004-09-21 | Tularik Inc. | CXCR3 antagonists |
SE0102716D0 (sv) * | 2001-08-14 | 2001-08-14 | Astrazeneca Ab | Novel compounds |
GB0221828D0 (en) * | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
GB0221829D0 (en) * | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
US7067658B2 (en) | 2002-09-30 | 2006-06-27 | Bristol-Myers Squibb Company | Pyridino and pyrimidino pyrazinones |
US6861422B2 (en) * | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
GB0328243D0 (en) * | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Methods |
US7271271B2 (en) | 2004-06-28 | 2007-09-18 | Amgen Sf, Llc | Imidazolo-related compounds, compositions and methods for their use |
US7375102B2 (en) | 2004-06-28 | 2008-05-20 | Amgen Sf, Llc | Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use |
US7939538B2 (en) | 2004-06-28 | 2011-05-10 | Amgen Inc. | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases |
DE102004033670A1 (de) * | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
US7759485B2 (en) * | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
US7728134B2 (en) * | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
US20060074088A1 (en) | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
DE102004058337A1 (de) | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten |
AU2005316668B2 (en) * | 2004-12-13 | 2012-09-06 | Millennium Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors |
AR053347A1 (es) | 2005-04-06 | 2007-05-02 | Astrazeneca Ab | Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos |
UA90707C2 (en) | 2005-04-06 | 2010-05-25 | Астразенека Аб | Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives |
US7439358B2 (en) * | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
EP2185559A1 (fr) | 2007-08-03 | 2010-05-19 | Boehringer Ingelheim International GmbH | Forme cristalline d'un dérivé de dihydroptéridione |
US20100016275A1 (en) * | 2008-07-16 | 2010-01-21 | Premji Meghani | Novel compound 395 |
US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
CN103717070A (zh) * | 2011-06-01 | 2014-04-09 | 贾纳斯生物治疗有限公司 | 新型免疫系统调节剂 |
CN110420316A (zh) | 2013-06-18 | 2019-11-08 | 纽约大学 | 参与金黄色葡萄球菌杀白细胞素的细胞毒性的细胞因素:新型治疗靶点 |
EP3024464A1 (fr) | 2013-07-26 | 2016-06-01 | Boehringer Ingelheim International GmbH | Traitement du syndrome myélodysplasique |
US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2924472A (en) | 1957-06-27 | 1960-02-09 | Gen Motors Corp | Pipe joint seal |
GB1009477A (en) | 1962-02-13 | 1965-11-10 | Smith Kline French Lab | Novel process for preparing heterocyclic compounds |
US3318900A (en) | 1964-05-06 | 1967-05-09 | Janssen Pharmaceutica Nv | Derivatives of benzimidazolinyl piperidine |
BE668603A (fr) | 1964-08-20 | |||
US3859287A (en) * | 1971-05-05 | 1975-01-07 | Walter Wesley Parish | Thiopteridines and process for producing same |
DE2331223C2 (de) | 1972-06-19 | 1984-11-22 | Kohjin Co., Ltd., Tokio / Tokyo | S-substituierte-2-Thioadenosine, deren 5'-Monophosphate, Verfahren zu deren Herstellung und Arzneimittel, welche diese enthalten |
US4120521A (en) | 1975-08-28 | 1978-10-17 | Rieber & Son Plastic-Industri A/S | Combined mould element and sealing ring |
EG12406A (en) | 1976-08-12 | 1979-03-31 | Janssen Pharmaceutica Nv | Process for preparing of novel n-aryl-n-(1-l-4-piperidinyl)-arylacetamides |
GB1600293A (en) | 1977-02-04 | 1981-10-14 | British Oceanics Ltd | Sealing arrangements |
US4188040A (en) | 1977-04-06 | 1980-02-12 | Firma WOCO Franz-Josef Wolf & Co. | Sealing ring |
DE2726959A1 (de) | 1977-06-15 | 1979-01-18 | Arlt Christian | Dichteinsatz zum dichten verbinden von zwei rohren |
FR2421899A1 (fr) | 1978-01-16 | 1979-11-02 | Roussel Uclaf | Nouveaux derives du tetrahydropyridinyl-indole et leurs sels, le procede de preparation et l'application a titre de medicaments de ces nouveaux produits |
US4410528A (en) | 1980-05-16 | 1983-10-18 | Kyowa Hakko Kogyo Co., Ltd. | Hypotensive piperidine derivatives |
DE3219522A1 (de) | 1981-10-28 | 1983-12-01 | Denso-Chemie Wedekind Kg, 5090 Leverkusen | Steckmuffendichtung fuer rohre |
FR2547888B1 (fr) | 1983-06-22 | 1985-12-13 | Sabla Sa | Bague d'etancheite a implants pour tuyaux a emboitement |
HU195822B (en) * | 1985-12-30 | 1988-07-28 | Gyogyszerkutato Intezet | Process for producing new pyrimido/5,4-b//1,h/oxazine derivatives |
CA1338012C (fr) | 1987-04-27 | 1996-01-30 | John Michael Mccall | Amines possedant des proprietes pharmaceutiques |
SE8800348L (sv) | 1988-02-03 | 1989-08-04 | Forsheda Ab | Taetningsring och verktyg foer framstaellning daerav |
FR2659656B1 (fr) | 1990-03-15 | 1994-09-09 | Sanofi Sa | Derives de pyrimidinedione-2,4 et medicaments les contenant. |
DE4119767A1 (de) | 1991-06-15 | 1992-12-17 | Dresden Arzneimittel | Verfahren zur herstellung von (pyrimid-2-yl-thio- bzw. seleno)-essigsaeurederivaten |
JP3100469B2 (ja) * | 1991-07-03 | 2000-10-16 | 中外製薬株式会社 | 乾癬治療剤 |
US5169161A (en) | 1991-09-19 | 1992-12-08 | Hail Mary Rubber Co., Inc. | Symmetrical gasket for pipe joints |
DE4134089C2 (de) | 1991-10-15 | 1994-10-13 | Dueker Eisenwerk | Schubgesicherte Muffenverbindung |
JPH05188994A (ja) | 1992-01-07 | 1993-07-30 | Sony Corp | 騒音抑圧装置 |
DE4229609C2 (de) | 1992-09-04 | 2003-05-08 | Forsheda Stefa Gmbh | Abdichtung zwischen zwei ineinandersteckbaren Teilen |
US5521197A (en) | 1994-12-01 | 1996-05-28 | Eli Lilly And Company | 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists |
PT778277E (pt) | 1995-12-08 | 2003-11-28 | Pfizer | Derivados heterociclicos substituidos como antagonistas do crf |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
SE515033C2 (sv) | 1995-12-27 | 2001-06-05 | Forsheda Ab | Tätningsanordning |
WO1997030035A1 (fr) | 1996-02-13 | 1997-08-21 | Zeneca Limited | Derives de la quinazoline utilises comme inhibiteurs du vegf |
DE69709319T2 (de) | 1996-03-05 | 2002-08-14 | Astrazeneca Ab | 4-anilinochinazolin derivate |
DE69736776T2 (de) | 1996-04-19 | 2007-01-18 | Neurosearch A/S | 1-(4-piperidyl)-benzimidazole mit neurotropher aktivität |
DE69736711T2 (de) | 1996-08-28 | 2007-09-20 | Pfizer Inc. | Substituierte 6,5-heterobicyclische-derivate |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
AU5522498A (en) | 1996-12-13 | 1998-07-03 | Merck & Co., Inc. | Substituted aryl piperazines as modulators of chemokine receptor activity |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
AU8576098A (en) | 1997-07-25 | 1999-02-16 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
AR013669A1 (es) | 1997-10-07 | 2001-01-10 | Smithkline Beecham Corp | Compuestos y metodos |
DE69817393T2 (de) | 1997-11-28 | 2004-06-17 | Sumitomo Pharmaceuticals Co., Ltd. | Neue heterozyklische verbindungen |
JP3342478B2 (ja) | 1998-01-19 | 2002-11-11 | ファイザー製薬株式会社 | Orl1−レセプターアゴニストとしての4−(2−ケト−1−ベンズイミダゾリニル)ピペリジン化合物 |
EP1070715A4 (fr) | 1998-03-19 | 2002-10-17 | Nihon Nohyaku Co Ltd | Derives d'arylpiperidine et utilisation de ceux-ci |
JP2002510695A (ja) | 1998-04-03 | 2002-04-09 | デュポン ファーマシューティカルズ カンパニー | 副腎皮質刺激ホルモン放出因子(CRF)拮抗剤としてのチアゾロ[4,5−d]ピリミジンおよびピリジン |
MA26659A1 (fr) | 1998-08-06 | 2004-12-20 | Pfizer | Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation. |
SE9802729D0 (sv) | 1998-08-13 | 1998-08-13 | Astra Pharma Prod | Novel Compounds |
US5988695A (en) | 1998-08-26 | 1999-11-23 | S&B Technical Products, Inc. | Pipe gasket with embedded ring |
PE20001420A1 (es) | 1998-12-23 | 2000-12-18 | Pfizer | Moduladores de ccr5 |
ES2229803T3 (es) * | 1998-12-28 | 2005-04-16 | 4 Aza Bioscience Nv | Efectos inmunosupresivos de derivados de pteridina. |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
CA2361561A1 (fr) * | 1999-02-02 | 2000-08-10 | K.U. Leuven Research & Development | Effets immunosuppresseurs des derives de pteridine |
US6248755B1 (en) | 1999-04-06 | 2001-06-19 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
US6142484A (en) | 1999-04-15 | 2000-11-07 | Vassallo Research & Development Corporation | Composite multi-pressure gasket |
AU5600100A (en) | 1999-06-11 | 2001-01-02 | Merck & Co., Inc. | Cyclopentyl modulators of chemokine receptor activity |
US6340681B1 (en) | 1999-07-16 | 2002-01-22 | Pfizer Inc | 2-benzimidazolylamine compounds as ORL-1-receptor agonists |
AU777468B2 (en) * | 1999-09-15 | 2004-10-21 | Warner-Lambert Company | Pteridinones as kinase inhibitors |
AR025884A1 (es) | 1999-10-01 | 2002-12-18 | Takeda Pharmaceutical | Compuestos de amina ciclica, su produccion y su uso |
SE9903544D0 (sv) | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
EP1122257B1 (fr) | 2000-01-05 | 2005-10-12 | Pfizer Inc. | Composés de benzimidazole comme agonistes du récepteur ORL1 |
GB2359078A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
GB2359081A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active thiazolopyrimidines |
JP2003522191A (ja) | 2000-02-11 | 2003-07-22 | アストラゼネカ・アクチエボラーグ | ケモカイン受容体活性のモジュレーターとしてのピリミジン化合物およびそれらの使用 |
GB2359079A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
GB2359551A (en) | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
GB0005642D0 (en) | 2000-03-10 | 2000-05-03 | Astrazeneca Uk Ltd | Chemical compounds |
WO2001070689A1 (fr) | 2000-03-24 | 2001-09-27 | Meiji Seika Kaisha, Ltd. | DERIVES DE LA DIPHENYLALKYLAMINE UTILES COMME AGONISTES DU RECEPTEUR DE L'OPIOIDE $g(d) |
IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
WO2002004434A1 (fr) | 2000-07-07 | 2002-01-17 | Angiogene Pharmaceuticals Limited | Derives de colchinol utilises comme agents de degradation vasculaire |
MXPA02012903A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como inhibidores de angiogenesis. |
SE0003828D0 (sv) | 2000-10-20 | 2000-10-20 | Astrazeneca Ab | Novel compounds |
SE0004110L (sv) | 2000-11-10 | 2002-05-11 | Forsheda Ab | Tätningsring |
SE0101322D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Novel compounds |
SE0102716D0 (sv) | 2001-08-14 | 2001-08-14 | Astrazeneca Ab | Novel compounds |
GB0221829D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
GB0221828D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
BRPI0415050A (pt) | 2003-10-07 | 2006-11-28 | Astrazeneca Ab | composto, formulação farmacêutica, método para tratar ou reduzir risco de uma doença ou condição humanas, uso de um composto ou de um sal deste farmaceuticamente aceitável, e, processo para a preparação de um composto ou de um sal deste farmaceuticamente aceitável |
GB0328243D0 (en) | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Methods |
WO2005082865A1 (fr) | 2004-02-27 | 2005-09-09 | Astellas Pharma Inc. | Dérivé de pyrimidine bicyclique fondu |
EP1844054A2 (fr) | 2004-12-17 | 2007-10-17 | AstraZeneca AB | Derives de thiazolopyrimidine pour la modulation de l'activite du recepteur chemokine |
-
2000
- 2000-02-23 GB GB0004128A patent/GB2359551A/en not_active Withdrawn
-
2001
- 2001-02-20 UA UA2002097583A patent/UA72590C2/uk unknown
- 2001-02-20 CZ CZ20022839A patent/CZ20022839A3/cs unknown
- 2001-02-20 US US10/204,814 patent/US6875868B2/en not_active Expired - Fee Related
- 2001-02-20 DE DE60100851T patent/DE60100851T2/de not_active Expired - Lifetime
- 2001-02-20 MX MXPA02008233A patent/MXPA02008233A/es active IP Right Grant
- 2001-02-20 NZ NZ520355A patent/NZ520355A/en not_active IP Right Cessation
- 2001-02-20 JP JP2001562540A patent/JP2003524012A/ja active Pending
- 2001-02-20 RU RU2002125451/04A patent/RU2002125451A/ru not_active Application Discontinuation
- 2001-02-20 AT AT01906493T patent/ATE250605T1/de active
- 2001-02-20 CN CNB018054676A patent/CN1190437C/zh not_active Expired - Fee Related
- 2001-02-20 KR KR1020027011047A patent/KR100795758B1/ko not_active IP Right Cessation
- 2001-02-20 SK SK1215-2002A patent/SK12152002A3/sk unknown
- 2001-02-20 TR TR2003/02214T patent/TR200302214T4/xx unknown
- 2001-02-20 EP EP01906493A patent/EP1259512B1/fr not_active Expired - Lifetime
- 2001-02-20 AU AU34316/01A patent/AU782509B2/en not_active Ceased
- 2001-02-20 WO PCT/SE2001/000374 patent/WO2001062758A1/fr not_active Application Discontinuation
- 2001-02-20 BR BR0108600-6A patent/BR0108600A/pt not_active Application Discontinuation
- 2001-02-20 ES ES01906493T patent/ES2206402T3/es not_active Expired - Lifetime
- 2001-02-20 PL PL01358004A patent/PL358004A1/xx not_active Application Discontinuation
- 2001-02-20 DK DK01906493T patent/DK1259512T3/da active
- 2001-02-20 HU HU0204399A patent/HUP0204399A3/hu unknown
- 2001-02-20 CA CA002400217A patent/CA2400217C/fr not_active Expired - Fee Related
- 2001-02-20 EE EEP200200461A patent/EE200200461A/xx unknown
- 2001-02-20 PT PT01906493T patent/PT1259512E/pt unknown
- 2001-02-20 IL IL15113201A patent/IL151132A0/xx unknown
- 2001-02-21 AR ARP010100773A patent/AR029805A1/es not_active Application Discontinuation
- 2001-02-21 CO CO01013781A patent/CO5290258A1/es not_active Application Discontinuation
-
2002
- 2002-08-07 IL IL151132A patent/IL151132A/en not_active IP Right Cessation
- 2002-08-07 IS IS6491A patent/IS6491A/is unknown
- 2002-08-14 BG BG107002A patent/BG107002A/bg unknown
- 2002-08-16 ZA ZA200206590A patent/ZA200206590B/en unknown
- 2002-08-22 NO NO20024005A patent/NO329898B1/no not_active IP Right Cessation
-
2003
- 2003-05-02 HK HK03103155A patent/HK1050899A1/xx not_active IP Right Cessation
-
2004
- 2004-07-15 US US10/891,833 patent/US7579342B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO329898B1 (no) | Pteridin forbindelser, fremgangsmate for fremstilling av slike, mellomprodukter, farmasoytiske sammensetninger og fremstilling omfattende slike, anvendelsen av slike i terapi samt anvendelse for fremstilling av medikamenter for behandling av sykdom | |
AU777872B2 (en) | Novel thiazolo(4,5-D)pyrimidine compounds | |
AU768004B2 (en) | Novel thiazolopyrimidine compounds | |
IL150952A (en) | Preparation of dosage forms of clear aqueous solution with bile acids | |
US20050234077A1 (en) | Pyrimidine compounds and their use as modulators of chemokine receptor activity | |
US20070142352A1 (en) | Pteridinone Derivatives as Modulators of Chemokine Receptor Activity | |
US20060111569A1 (en) | Thiazolopyrimidines and their use as modulators of chemokine receptor activity | |
EP1257555B1 (fr) | Composes pyrimidiniques et leur utilisation comme modulateurs de l'activite des recepteurs de chimiokine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |